MedDRA - 10048610: Cardiotoxicity C74 C64
Conditions
Interventions
Group 1: After consenting to participate in the study, a biosample (blood or saliva) is obtained for DNA extraction and patients undergo an echocardiographic examination. Genotyping for candidate sing
Sponsors
Studienleiter des Late Effects Surveillance System (LESS)Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Schleswig-Holstein, Campus Lübeck
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients are invited to participate if they: (a) were diagnosed with nephroblastoma or neuroblastoma between January 1990 and December 2012, (b) had the diagnosis before the age of 18, (c) were treated with anthracyclines, and (d) had participated in one of the nephroblastoma trials SIOP 9/GPOH, SIOP 93-01/GPOH, or SIOP 2001/GPOH or neuroblastoma trials NB 90, NB 97, or NB 2004.
Exclusion criteria
Exclusion criteria: Non-consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of high vs. moderate and low genetic risk of anthracycline-associated cardiotoxicity (according to RARG rs2229774, UGT1A6 rs17863783and SLC28A3 rs7853758 genotypes) with the incidence of anthracycline-associated cardiomyopathy, as confirmed by echocardiography. Echocardiography is performed as part of routine follow-up examinations within 12 months from inclusion of the patient. | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of the pharmacogenetic profile (candidate genes and genome-wide) between patients without and patients with anthracycline-associated cardiotoxicity, as confirmed by echocardiography. Echocardiography is performed as part of routine follow-up examinations within 12 months from inclusion of the patient. | — |
Countries
Germany
Contacts
Public ContactOliver Zolk
Institut für Naturheilkunde & Klinische Pharmakologie,Universitätsklinikum Ulm
Outcome results
None listed